TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
SYRE

Spyre Therapeutics Inc.

Healthcare · Biotechnology

92.00$ -0.1% vs. previous close Closing price · As of: Sep 22, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement SYRE
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
1.5% 10.7% 84.3% 108.8% 108.8%
98.5% 100.0% 100.0% 100.0% 100.0% 100.0% -8.8% 100.0%
188.2% 392.0% 438.3% 944.4% 304.5% 2,515.2% 10,102.0% 18,373.6%
97.7% 145.8% 1,225.0% 4,508.6% 5,166.6%
285.9% 573.3% 631.7% 1,269.3% 450.3% 3,740.2% 27,448.0% 23,540.2%
-185.9% -473.3% -531.7% -1,169.3% -350.3% -3,640.2% -27,348.0% -23,540.2%
-185.6% -468.8% -523.3% -1,140.6% -350.4% -3,604.6% -38,241.1% -23,472.6%
0.8% -5.8% -2.9% 5.8%
-185.6% -468.8% -523.3% -1,140.6% -351.1% -3,598.8% -38,238.1% -23,478.3%
-184.5% -470.5% -526.9% -1,161.8% -342.0% -3,520.3% -27,348.0% -23,472.6%

Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?